Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
Mené sur 228 patients atteints d'un cancer du poumon non à petites cellules non épidermoïde EGFR+ de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du bévacizumab à l'erlotinib (durée médiane de suivi : 12,4 mois)
The first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) with a common EGFR mutation is EGFR tyrosine kinase inhibitor (TKI) monotherapy. Once patients have disease progression and continuing treatment is deemed inappropriate, patients with EGFR Thr790Met resistance mutations are switched to osimertinib, or to pemetrexed and cisplatin if osimertinib was the first-line treatment. Subsequent treatment after disease progression following second-line treatment is more complicated and should be personalised according to clinical manifestations and genomic tumour alterations. Recent clinical trials have shown that median overall survival for patients with EGFR-positive NSCLC ranges between 3 and 5 years
The Lancet Oncology , commentaire, 2018